Lisa was initially diagnosed with advanced non-small cell lung cancer, and was told to prepare for hospice. In search of another option, she approached a new physician. Watch the video to see how–despite the tumor showing no genomic targets with a standard gene panel– Lisa's physician was able to personalize her chemotherapy to achieve complete remission.
The Era of Complete Genomics and Proteomics is Here
GPS Cancer is the most comprehensive molecular profile available, integrating whole genome (DNA) sequencing of both tumor and normal tissue, whole transcriptome (RNA) sequencing, and quantitative proteomics by mass spectrometry to inform personalized treatment strategies.
Increasingly, clinical evidence is revealing the predictive value of protein expression measurement in selecting patients who will benefit from commonly used chemotherapies. In cases like Lisa’s, GPS Cancer can provide insight into expression levels of multiple clinically-relevant proteins, which can suggest new treatment options that may not have been considered.
- Quantitative Mass Spectrometry Proteomics Identifies FRalpha and GARFT as Predictive Biomarkers in NSCLC Patients Treated With Pemetrexed**
- Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial**
Ready to order GPS Cancer? Contact the GPS Cancer Center at 1-844-MY-OMICS or at GPSCancer@NantHealth.com to get started.
To learn more about GPS Cancer, fill out the form below:
*Disclaimer: These tests have not been cleared or approved by the FDA. Both laboratories are regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test is used for clinical purposes. It should not be regarded as investigational or for research. The test report makes no promises or guarantees that a particular drug will be effective in the treatment of a disease in any patient. Decisions regarding care and treatment should not be based on a single test such as this test. Rather, decisions on care and treatment should be based on the independent medical judgment of the treating physician taking into consideration all available information concerning the patient ’s condition, including other pathological tests, in accordance with the standard of care in a given community. The test report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.
**One or more study investigators are employed by the Nant ecosystem of companies.